- Home
- IMPP vs ACRS Comparison
IMPP vs ACRS Comparison
Compare IMPP & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMPP | ACRS |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.7M | 868.5M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | IMPP | ACRS |
|---|---|---|
| Price | $5.75 | $5.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $10.20 |
| AVG Volume (30 Days) | 505.5K | ★ 2.4M |
| Earning Date | 05-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $51.79 | N/A |
| Revenue Next Year | $6.97 | $4.24 |
| P/E Ratio | $3.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.15 | $1.74 |
| 52 Week High | $6.57 | $6.60 |
Technical Indicators
Market Signals| Indicator | IMPP | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 64.45 | 42.44 |
| Support Level | $4.64 | $4.13 |
| Resistance Level | N/A | $5.87 |
| Average True Range (ATR) | 0.24 | 0.33 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 73.22 | 36.99 |
Price Performance
Historical ComparisonAbout IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.